Tesamorelin

Tesamorelin is a synthetic Growth Hormone Releasing Hormone (GHRH) analog that stimulates the pituitary gland to release the body's own growth hormone (GH). It is FDA-approved as Egrifta SV for the reduction of excess abdominal visceral fat in adults with HIV-associated lipodystrophy.

Outside of this indication, tesamorelin is used off-label for:

• Reduction of visceral (deep abdominal) fat
• Body composition improvement
• Recovery and performance optimization
• Growth hormone deficiency support
• Metabolic health optimization

Unlike growth hormone injections, tesamorelin does not contain growth hormone itself. Instead, it stimulates the body's natural growth hormone production.

Book Now

How Is Tesamorelin Administered?

Administered as:

• Subcutaneous injection (SQ)

Common injection sites:

• Abdomen
• Upper arm

FDA-approved dose:

• 2 mg SQ once daily

(many people take 1mg daily)

Most protocols administer tesamorelin:

• Once daily
• In the evening before bed & 2-3 hours after last meal
• Usually on an empty stomach when possible

Why at night?

Growth hormone is naturally released in pulses, with the largest pulse occurring shortly after falling asleep. Administering tesamorelin in the evening may better align with this natural rhythm.

Many patients reassess use after:

3 months
6 months

this is usually enough time to determine whether meaningful benefit is occurring.

When to Stop:

Treatment is generally discontinued if:

• Significant side effects develop
• Desired goals are achieved
• Pregnancy occurs
• Excessive IGF-1 elevation develops*
• A provider recommends discontinuation

Unlike exogenous growth hormone, tesamorelin generally does not completely suppress the body's natural GH production because it works upstream through the pituitary gland.

*What happens if IGF-1 gets too high?

This is one of the main reasons to monitor blood work while taking Tesamorelin long-term.

Early signs

Common symptoms include:

Fluid retention
Puffy face
Swollen fingers
Joint pain
Numbness or tingling
Carpal tunnel symptoms
Headaches

If IGF-1 remains elevated:

Insulin resistance may worsen
Blood sugar may increase

Extreme elevations

Very prolonged elevations can theoretically contribute to:

Organ enlargement
Soft tissue overgrowth

This is what happens in the disease: acromegaly. However, people often misunderstand this risk. The concern is not a mildly elevated IGF-1 for a few months. The concern is significant elevation for years without monitoring.

The levels seen with monitored tesamorelin therapy are typically far lower than what is seen in acromegaly.

What happens after stopping tesamorelin in general? The biggest issue isn't hormone suppression. It's that many of the benefits fade.

Studies have shown:

IGF-1 falls back toward baseline
GH secretion returns toward baseline
Visceral fat often gradually returns

In other words:

Tesamorelin doesn't permanently change your body's fat-storage tendencies. Once treatment stops, physiology tends to move back toward its previous state.

Common effects:

• Injection site reactions
• Redness
• Swelling
• Itching
• Joint discomfort
• Muscle aches
• Fluid retention
• Mild swelling
• Headache

Less common effects:

• Numbness or tingling
• Increased blood sugar*
• Carpal tunnel-like symptoms

Rare:

• Allergic reactions
• Significant edema
• Excessive IGF-1 elevation

*How does tesamorelin raise blood sugar? This surprises many people because tesamorelin often reduces body fat. The answer is that growth hormone and insulin have opposing effects in several tissues.

Insulin tells cells:

"Take glucose out of the bloodstream and use or store it."

Result:

Lower blood sugar

Growth hormone tells the body:

"Mobilize stored fuel and preserve glucose."

Result:

Increased fat breakdown
Increased free fatty acids in circulation
Reduced insulin sensitivity

What actually happens? Growth hormone increases lipolysis. This releases free fatty acids into the bloodstream.

Those fatty acids interfere with insulin signaling in muscle and liver.

As a result:

Muscles become less responsive to insulin
Less glucose enters cells
More glucose remains in the bloodstream

The result can be:

Higher fasting glucose
Higher fasting insulin
Mild insulin resistance

This is why:

Growth hormone injections
Tesamorelin
Other GH secretagogues

can all increase blood sugar despite reducing body fat.

Does everyone become diabetic? No. Most healthy individuals experience only mild changes.

However, people with:

Prediabetes
Diabetes
Significant insulin resistance

should be monitored carefully.

How does fluid retention happen? Fluid retention is one of the most common side effects. What causes it?

Growth hormone increases:

Sodium retention in the kidneys
Water retention

Water follows sodium.

As a result:

Hands may feel tight
Rings may fit differently
Ankles may swell
Scale weight may increase

How Does Tesamorelin Work In The Body?

1. What Is Tesamorelin?

Tesamorelin is a synthetic analog of Growth Hormone Releasing Hormone (GHRH). Normally, the hypothalamus releases GHRH.

Hypothalamus
↓
GHRH
↓
Pituitary gland
↓
Growth Hormone
↓
Liver
↓
IGF-1

Tesamorelin essentially mimics the body's natural GHRH signal. Rather than supplying growth hormone directly, it tells the pituitary gland to release more of the growth hormone the body already produces.

How does tesamorelin work with the body's negative feedback system? This is where tesamorelin differs significantly from growth hormone injections.

When IGF-1 rises:

The body recognizes that enough GH activity exists.

The brain responds by:

Releasing less GHRH
Releasing more somatostatin

What is somatostatin? Somatostatin is essentially the body's: "Stop making growth hormone."

signal. It acts as a brake on GH production.

Where tesamorelin fits: Tesamorelin is a synthetic version of GHRH. It stimulates the pituitary to release GH.

However, it does not remove the brakes. The body can still respond to rising IGF-1 by increasing somatostatin and reducing GH release.
Think of it like:

Tesamorelin = pressing the gas pedal

Somatostatin = brakes

The brakes still work.

Does tesamorelin mess up the feedback system?

Current evidence suggests:

Not significantly. Unlike directly injecting growth hormone, tesamorelin still relies on the body's natural regulatory pathways.

The body continues to:

Sense IGF-1
Increase somatostatin
Reduce native GHRH production

Another important point:

Tesamorelin requires a functioning pituitary. If the pituitary decides GH levels are already high enough, the response to tesamorelin becomes more limited. What happens to the feedback system after stopping?

Current evidence suggests:

GH returns toward baseline
IGF-1 returns toward baseline
Normal feedback mechanisms continue functioning

There is no evidence that tesamorelin permanently damages the GH axis.

This is very different from:

Testosterone therapy
Anabolic steroid use

Those therapies directly suppress hormone production upstream. Tesamorelin stimulates a system that remains under physiologic control.

Do people need post-cycle therapy? Generally no. Post-cycle therapy is not typically used after tesamorelin. The pituitary does not appear to become permanently suppressed.

2. Growth Hormone Release

The pituitary gland contains specialized cells called somatotrophs. These cells produce and release growth hormone. When tesamorelin binds to GHRH receptors on these cells, it increases growth hormone secretion.

Importantly, growth hormone release remains pulsatile. This differs from administering exogenous growth hormone, which introduces GH directly into circulation. Because tesamorelin uses the body's existing regulatory system, feedback mechanisms remain partially intact.

3. IGF-1 Production

Many of growth hormone's effects occur through a hormone called Insulin-Like Growth Factor 1 (IGF-1).

Growth Hormone
↓
Liver stimulation
↓
IGF-1 production

IGF-1 contributes to:

• Protein synthesis
• Tissue repair
• Muscle maintenance
• Bone metabolism
• Recovery processes

Much of tesamorelin's clinical effect is ultimately mediated through increased IGF-1 levels.

4. Why Visceral Fat Decreases

One of tesamorelin's most unique characteristics is its effect on visceral adipose tissue.

There are two major categories of body fat:

Subcutaneous fat:
• Located under the skin
• Can be pinched

Visceral fat:
• Located deep within the abdomen
• Surrounds internal organs

Visceral fat is associated with:

• Insulin resistance
• Cardiovascular disease
• Metabolic dysfunction

Growth hormone increases lipolysis (fat breakdown). Visceral fat appears particularly sensitive to growth hormone signaling.

As GH and IGF-1 levels increase:

• Fat breakdown increases
• Fat oxidation increases
• Visceral fat stores decrease

This is why tesamorelin earned FDA approval for HIV-associated visceral fat accumulation.

An important point: Tesamorelin is not a weight-loss drug. Many patients lose relatively little scale weight but experience meaningful reductions in waist circumference and visceral fat.

5. Effects on Muscle and Body Composition

Growth hormone is often thought of as a muscle-building hormone. In reality, its effects are more nuanced.

Tesamorelin primarily:

• Preserves lean mass
• Supports recovery
• Improves body composition

Rather than causing dramatic muscle growth, tesamorelin tends to improve the ratio of fat mass to lean mass.

Resistance training and adequate protein intake remain the primary drivers of muscle growth.

6. Why Tesamorelin Is Different From Growth Hormone?

Many people assume tesamorelin and growth hormone are the same. They are not.

Growth Hormone Injection:
• Delivers GH directly
• Bypasses pituitary regulation
• Higher risk of excessive exposure

Tesamorelin:
• Stimulates natural GH release
• Uses existing feedback systems
• Produces more physiologic hormone patterns

Think of tesamorelin as turning up the body's GH production rather than replacing it.

Effects in Healthy Individuals:

Most tesamorelin research has been conducted in HIV-associated lipodystrophy and metabolic disease.

In healthy individuals, potential effects may include:

• Reduced visceral fat
• Improved body composition
• Increased IGF-1 levels
• Mild fluid retention
• Improved recovery

Potential concerns include:

• Elevated blood sugar
• Excessive IGF-1 levels
• Fluid retention
• Joint discomfort
• Carpal tunnel symptoms

For already lean individuals with low visceral fat, benefits may be substantially smaller than those seen in clinical trials.

How Can Tesamorelin Support Athletes?

Tesamorelin has become increasingly popular among athletes and bodybuilders interested in optimizing body composition. By stimulating the body's natural release of growth hormone, it is being explored for its potential to support lean body composition, metabolic health, and recovery when paired with consistent training and nutrition. Because these uses are off-label, treatment should always be individualized and medically supervised.

How Does Tesamorelin Affect Women & Their Hormones?

Tesamorelin does not directly act on:

Estrogen
Progesterone
Testosterone
LH
FSH

Instead, it works on the growth hormone (GH) / IGF-1 axis.

How it may indirectly affect female hormones:

1. Changes in body fat

Fat tissue isn't just storage tissue—it also functions as an endocrine organ. Fat cells contain the enzyme aromatase, which converts androgens into estrogen.

If tesamorelin leads to significant fat loss:

Less aromatase activity may occur
Estrogen production from fat tissue may decrease

This is usually not clinically significant, but in women who become very lean, menstrual cycle changes can occur.

2. IGF-1 interacts with the ovaries

The ovaries contain IGF-1 receptors.

IGF-1 helps regulate:

Follicle development
Egg maturation
Ovarian hormone production

Because of this, significant changes in IGF-1 levels can influence reproductive hormone signaling. However, menstrual irregularities are not considered a common side effect of tesamorelin.

3. Changes in insulin sensitivity

Growth hormone can temporarily reduce insulin sensitivity.

Since insulin also interacts with ovarian function, women with conditions such as:

Polycystic Ovary Syndrome

Tesamorelin

How Is Tesamorelin Administered?

How Does Tesamorelin Work In The Body?

1. What Is Tesamorelin?

Tesamorelin is a synthetic analog of Growth Hormone Releasing Hormone (GHRH). Normally, the hypothalamus releases GHRH.

Hypothalamus ↓ GHRH ↓ Pituitary gland ↓ Growth Hormone ↓ Liver ↓ IGF-1

Tesamorelin essentially mimics the body's natural GHRH signal. Rather than supplying growth hormone directly, it tells the pituitary gland to release more of the growth hormone the body already produces.

How does tesamorelin work with the body's negative feedback system? This is where tesamorelin differs significantly from growth hormone injections.

When IGF-1 rises:

The body recognizes that enough GH activity exists.

The brain responds by:

Releasing less GHRH

Releasing more somatostatin

What is somatostatin? Somatostatin is essentially the body's: "Stop making growth hormone."

signal. It acts as a brake on GH production. Where tesamorelin fits: Tesamorelin is a synthetic version of GHRH. It stimulates the pituitary to release GH.

However, it does not remove the brakes. The body can still respond to rising IGF-1 by increasing somatostatin and reducing GH release. Think of it like:

Tesamorelin = pressing the gas pedal

Somatostatin = brakes

The brakes still work.

Does tesamorelin mess up the feedback system?

Current evidence suggests:

Not significantly. Unlike directly injecting growth hormone, tesamorelin still relies on the body's natural regulatory pathways.

The body continues to:

Sense IGF-1

Increase somatostatin

Reduce native GHRH production

Another important point:

Tesamorelin requires a functioning pituitary. If the pituitary decides GH levels are already high enough, the response to tesamorelin becomes more limited. What happens to the feedback system after stopping?

Current evidence suggests:

GH returns toward baseline

IGF-1 returns toward baseline

Normal feedback mechanisms continue functioning

There is no evidence that tesamorelin permanently damages the GH axis.

This is very different from:

Testosterone therapy

Anabolic steroid use

Those therapies directly suppress hormone production upstream. Tesamorelin stimulates a system that remains under physiologic control.

Do people need post-cycle therapy? Generally no. Post-cycle therapy is not typically used after tesamorelin. The pituitary does not appear to become permanently suppressed.

2. Growth Hormone Release

The pituitary gland contains specialized cells called somatotrophs. These cells produce and release growth hormone. When tesamorelin binds to GHRH receptors on these cells, it increases growth hormone secretion.

Importantly, growth hormone release remains pulsatile. This differs from administering exogenous growth hormone, which introduces GH directly into circulation. Because tesamorelin uses the body's existing regulatory system, feedback mechanisms remain partially intact.

3. IGF-1 Production

Many of growth hormone's effects occur through a hormone called Insulin-Like Growth Factor 1 (IGF-1).

Growth Hormone ↓ Liver stimulation ↓ IGF-1 production

IGF-1 contributes to:

• Protein synthesis • Tissue repair • Muscle maintenance • Bone metabolism • Recovery processes

Much of tesamorelin's clinical effect is ultimately mediated through increased IGF-1 levels.

4. Why Visceral Fat Decreases

One of tesamorelin's most unique characteristics is its effect on visceral adipose tissue.

There are two major categories of body fat:

Subcutaneous fat: • Located under the skin • Can be pinched

Visceral fat: • Located deep within the abdomen • Surrounds internal organs

Visceral fat is associated with:

• Insulin resistance • Cardiovascular disease • Metabolic dysfunction

Growth hormone increases lipolysis (fat breakdown). Visceral fat appears particularly sensitive to growth hormone signaling.

As GH and IGF-1 levels increase:

• Fat breakdown increases • Fat oxidation increases • Visceral fat stores decrease

This is why tesamorelin earned FDA approval for HIV-associated visceral fat accumulation.

An important point: Tesamorelin is not a weight-loss drug. Many patients lose relatively little scale weight but experience meaningful reductions in waist circumference and visceral fat.

5. Effects on Muscle and Body Composition

Growth hormone is often thought of as a muscle-building hormone. In reality, its effects are more nuanced.

Tesamorelin primarily:

• Preserves lean mass • Supports recovery • Improves body composition

Rather than causing dramatic muscle growth, tesamorelin tends to improve the ratio of fat mass to lean mass.

Resistance training and adequate protein intake remain the primary drivers of muscle growth.

6. Why Tesamorelin Is Different From Growth Hormone?

Many people assume tesamorelin and growth hormone are the same. They are not.

Growth Hormone Injection: • Delivers GH directly • Bypasses pituitary regulation • Higher risk of excessive exposure

Tesamorelin: • Stimulates natural GH release • Uses existing feedback systems • Produces more physiologic hormone patterns

Think of tesamorelin as turning up the body's GH production rather than replacing it.

Effects in Healthy Individuals:

Most tesamorelin research has been conducted in HIV-associated lipodystrophy and metabolic disease.

In healthy individuals, potential effects may include:

• Reduced visceral fat • Improved body composition • Increased IGF-1 levels • Mild fluid retention • Improved recovery

Potential concerns include:

• Elevated blood sugar • Excessive IGF-1 levels • Fluid retention • Joint discomfort • Carpal tunnel symptoms

For already lean individuals with low visceral fat, benefits may be substantially smaller than those seen in clinical trials.

How Can Tesamorelin Support Athletes?

How Does Tesamorelin Affect Women & Their Hormones?

Tesamorelin does not directly act on:

Hypothalamus
↓
GHRH
↓
Pituitary gland
↓
Growth Hormone
↓
Liver
↓
IGF-1

signal. It acts as a brake on GH production.

Where tesamorelin fits: Tesamorelin is a synthetic version of GHRH. It stimulates the pituitary to release GH.

However, it does not remove the brakes. The body can still respond to rising IGF-1 by increasing somatostatin and reducing GH release.
Think of it like:

Growth Hormone
↓
Liver stimulation
↓
IGF-1 production

• Protein synthesis
• Tissue repair
• Muscle maintenance
• Bone metabolism
• Recovery processes

Subcutaneous fat:
• Located under the skin
• Can be pinched

Visceral fat:
• Located deep within the abdomen
• Surrounds internal organs

• Insulin resistance
• Cardiovascular disease
• Metabolic dysfunction

• Fat breakdown increases
• Fat oxidation increases
• Visceral fat stores decrease

• Preserves lean mass
• Supports recovery
• Improves body composition

Growth Hormone Injection:
• Delivers GH directly
• Bypasses pituitary regulation
• Higher risk of excessive exposure

Tesamorelin:
• Stimulates natural GH release
• Uses existing feedback systems
• Produces more physiologic hormone patterns

• Reduced visceral fat
• Improved body composition
• Increased IGF-1 levels
• Mild fluid retention
• Improved recovery

• Elevated blood sugar
• Excessive IGF-1 levels
• Fluid retention
• Joint discomfort
• Carpal tunnel symptoms